Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma
NL-OMON46260Phase 2Withdrawn
- Sponsor
- Curis, Inc.
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fimepinostat in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and follicular lymphoma (FL) (3 arms), sponsored by Curis, Inc. Primary endpoint: Objective response rate in Group B. Planned start Jul 2016; status: withdrawn.
02
Drugs
fimepinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma (FL)
Beyond the preview
Go deeper on NL-OMON46260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46260.